Zobrazeno 1 - 10
of 43
pro vyhledávání: '"C F, Abildgaard"'
Autor:
Jeanne M. Lusher, P. M. Mannucci, Steven Arkin, D. Hurst, C F Abildgaard, L. Schwartz, R. Zimmermann
Publikováno v:
Journal of Thrombosis and Haemostasis. 2:574-583
Summary. Background: Development of recombinant factor VIII (rFVIII) replacement therapy represents a milestone in the treatment of hemophilia A. Objective: The objective of this long-term, multicenter study was to assess the safety, efficacy and rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cd07c303737c5eecd88ceba717beeec
https://doi.org/10.1111/j.1538-7933.2004.00646.x
https://doi.org/10.1111/j.1538-7933.2004.00646.x
Publikováno v:
Haemophilia. 5:9-16
Fifty-eight previously treated haemophilic subjects were treated exclusively with the recombinant FVIII (rFVIII-KOGENATE) produced by Bayer Corporation (Berkeley, CA) in an international multicentre prospective study of more than 5 years duration. Fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9576efa3a6d13044cbda38223b81c6a
https://doi.org/10.1046/j.1365-2516.1999.00191.x
https://doi.org/10.1046/j.1365-2516.1999.00191.x
Autor:
D Hurst, Louis M. Aledort, P. M. Mannucci, C F Abildgaard, R S Schwartz, Doreen B. Brettler, Jeanne M. Lusher
Publikováno v:
Blood. 83:1958-1962
Recent studies suggest that treatment of hemophiliacs with highly purified factor VIII concentrates may preserve immune function. To test this hypothesis, we prospectively studied 51 hemophilic patients (21 human immunodeficiency virus [HIV] seroposi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2fe5a38d259cc4b67338c3bb267daca4
https://doi.org/10.1182/blood.v83.7.1958.1958
https://doi.org/10.1182/blood.v83.7.1958.1958
Autor:
Carol K. Kasper, JeanneM. Lusher, J Addiego, Bertil Glader, C F Abildgaard, L Aledort, Margaret W. Hilgartner
Publikováno v:
The Lancet. 342:462-464
Clinical studies evaluating highly purified monoclonal-antibody-derived and recombinant-DNA-derived clotting factor concentrates in previously untreated (PUPS) severe factor VIII (FVIII) deficient haemophilia patients, have documented an increased fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::084e6e7ae4892d369bbdaec6cc1ed012
https://doi.org/10.1016/0140-6736(93)91593-b
https://doi.org/10.1016/0140-6736(93)91593-b
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 5(1)
Fifty-eight previously treated haemophilic subjects were treated exclusively with the recombinant FVIII (rFVIII-KOGENATE) produced by Bayer Corporation (Berkeley, CA) in an international multicentre prospective study of more than 5 years duration. Fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb175001febcc0fa00f26af8bae45aef
https://pubmed.ncbi.nlm.nih.gov/10215942
https://pubmed.ncbi.nlm.nih.gov/10215942
Publikováno v:
American Journal of Public Health. 80:967-969
Thirteen hemophilia centers provide comprehensive care to approximately 90 percent of persons with hemophilia in California. For 1987, these centers reported patient human immunodeficiency virus (HIV) antibody status, age group, level of clotting fac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3659452b9b44f1226bbe5321a6805cc
https://doi.org/10.2105/ajph.80.8.967
https://doi.org/10.2105/ajph.80.8.967
Autor:
M A, Jarvis, L G, Levin, J A, Harrison, D J, DePianto, C M, Suzuki, C L, Ziaja, J E, Brown, K W, Jolly, H M, Reisner, C F, Abildgaard, J S, Powell
Publikováno v:
Thrombosis and haemostasis. 75(2)
Hemophilia A is a clotting disorder that is due to reduced or absent coagulation factor VIII (FVIII) activity. In approximately 25% of people with severe hemophilia A, standard treatment with intravenous plasma-derived or recombinant FVIII (rFVIII) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c9b9e674951e0f7f09f479ca6d3f02db
https://pubmed.ncbi.nlm.nih.gov/8815584
https://pubmed.ncbi.nlm.nih.gov/8815584
Publikováno v:
The American journal of pediatric hematology/oncology. 15(3)
Alpha 2-Antiplasmin (AP) deficiency is a rare congenital bleeding disorder that presents with normal screening tests for platelet function and clotting. We believe that this disorder is frequently overlooked, especially in women with unexplained blee
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::35a9699999c1ef043022f10c54e61284
https://pubmed.ncbi.nlm.nih.gov/8328647
https://pubmed.ncbi.nlm.nih.gov/8328647
Publikováno v:
The New England journal of medicine. 328(7)
Although methods of viral attenuation in plasma-derived clotting-factor concentrates have improved, there is still a possibility that such concentrates may transmit certain blood-borne viruses. For this reason, the use of recombinant DNA-derived fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0e8afb77a0e787de8e22b52e6ec8036e
https://pubmed.ncbi.nlm.nih.gov/8421474
https://pubmed.ncbi.nlm.nih.gov/8421474
Autor:
C F, Abildgaard
Publikováno v:
Seminars in hematology. 28(2 Suppl 1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d0cdb6c9dde3064be422d6d30f8d3122
https://pubmed.ncbi.nlm.nih.gov/1908127
https://pubmed.ncbi.nlm.nih.gov/1908127